GlaxoSmithKline, Sanofi strike deal to develop coronavirus vaccine

GlaxoSmithKline and Sanofi SA said on Tuesday they would develop a vaccine to fight the fast-spreading coronavirus.
 

The drugmakers said they expect to start clinical trials for the vaccine in the second half of this year. If successful, the vaccine would be available in the second half of 2021. The announcement comes at a time when drugmakers are pausing clinical trials for other disease areas as they focus on testing potential treatments for the coronavirus.
 

The adjuvanted vaccine will be developed by combining Sanofi's S-protein Covid-19 antigen and GSK's pandemic adjuvant technology.